Trials / Completed
CompletedNCT02444221
Rivaroxaban Evaluation in Real Life Settings
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,278 (actual)
- Sponsor
- Thrombosis Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice.
Detailed description
This large global registry focuses on studying Atrial Fibrillation (AF) and evaluating characteristics, management and outcomes of patients treated with Rivaroxaban. The RIVER registry is observational, decisions on patient management are determined by the health care professional and the patient and not by the protocol. Patients are therefore treated according to normal local practice and the drug label/relevant product information of any drugs administered to them.
Conditions
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2019-05-30
- Completion
- 2020-09-30
- First posted
- 2015-05-14
- Last updated
- 2021-05-07
Locations
2 sites across 2 countries: France, United Kingdom
Source: ClinicalTrials.gov record NCT02444221. Inclusion in this directory is not an endorsement.